key: cord-0943687-pltg86m8
authors: South, K.; Roberts, L.; Morris, L. V.; Mann, E.; Menon, M.; Knight, S.; Konkel, J. E.; Ustianowsk, A.; Bakerly, N. D.; Dark, P. M.; Simpson, A.; Felton, T.; Horsley, A.; CIRCO,; Hussell, T.; Grainger, J. R.; Smith, C. J.; Allan, S. M.
title: Severity-stratified and longitudinal analysis of VWF/ADAMTS13 imbalance, altered fibrin crosslinking and inhibition of fibrinolysis as contributors to COVID-19 coagulopathy
date: 2020-08-21
journal: nan
DOI: 10.1101/2020.08.18.20159608
sha: 83bd8e088444ae1e01e8b5cb2e012ba2e4ca205c
doc_id: 943687
cord_uid: pltg86m8

Background: Early clinical reports have suggested that the prevalence of thrombotic complications in the pathogenesis of COVID-19 may be as high as 30% in intensive care unit (ICU)-admitted patients and could be a major factor contributing to mortality. However, mechanisms underlying COVID-19-associated thrombo-coagulopathy, and its impact on patient morbidity and mortality, are still poorly understood. Methods: We performed a comprehensive analysis of coagulation and thromboinflammatory factors in plasma from COVID-19 patients with varying degrees of disease severity. Furthermore, we assessed the functional impact of these factors on clot formation and clot lysis. Results: Across all COVID-19 disease severities (mild, moderate and severe) we observed a significant increase (6-fold) in the concentration of ultra-large von Willebrand factor (UL-VWF) multimers compared to healthy controls. This is likely the result of an interleukin (IL)-6 driven imbalance of VWF and the regulatory protease ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs, member 13). Upregulation of this key pro-coagulant pathway may also be influenced by the observed increase (~6-fold) in plasma -defensins, a consequence of increased numbers of neutrophils and neutrophil activation. Markers of endothelial, platelet and leukocyte activation were accompanied by increased plasma concentrations of Factor XIII (FXIII) and plasminogen activator inhibitor (PAI)-1. In patients with high FXIII we observed alteration of the fibrin network structure in in vitro assays of clot formation, which coupled with increased PAI-1, prolonged the time to clot lysis by the t-PA/plasmin fibrinolytic pathway by 52% across all COVID-19 patients (n=23). Conclusions: We show that an imbalance in the VWF/ADAMTS13 axis causing increased VWF reactivity may contribute to the formation of platelet-rich thrombi in the pulmonary vasculature of COVID-19 patients. Through immune and inflammatory responses, COVID-19 also alters the balance of factors involved in fibrin generation and fibrinolysis which accounts for the persistent fibrin deposition previously observed in post-mortem lung tissue.

 In all COVID-19 patients, even mild cases, UL-VWF is present in plasma due to the alteration of VWF 23 and ADAMTS13 concentrations, likely driven by increased IL-6 and α-defensins. 24 25

 Increased plasma FXIII alters fibrin structure and enhances incorporation of VWF into fibrin clusters. 26 27

 Defective fibrin structure, coupled with increased plasma PAI-1 and α2-antiplasmin, inhibits 28 fibrinolysis by t-PA/plasmin. 29

What are the clinical implications? 30  Prophylactic anticoagulation and management of thrombotic complications in COVID-19 patients are  31 ongoing challenges requiring a better understanding of the coagulopathic mechanisms involved. 32 33

 We have identified FXIII and VWF as potential therapeutic targets for treating fibrin formation 34 defects in COVID-19 patients. 35 36

 We have identified a multifaceted fibrinolytic resistance in COVID-19 patient plasma with potential 37

implications in the treatment of secondary thrombotic events such as acute ischaemic stroke or 38 massive pulmonary embolism. The severe acute respiratory syndrome coronavirus (SARS-CoV)-2 pandemic, since its origin in December 2019, has 2 affected more than 20 million individuals worldwide resulting in almost 750,000 fatalities. The diseased state 3 induced by the virus, coronavirus disease 2019 , manifests as a broad clinical spectrum ranging from 4 asymptomatic individuals, through to a mild flu-like illness and, in a small proportion of people, a severe hyper-5 inflammatory state causing acute respiratory distress syndrome (ARDS), multiple organ failure and death. Early 6 clinical and post-mortem observations also indicated the existence of a hyper-coagulative state, seemingly distinct 7 from sepsis-induced disseminated intravascular coagulation (DIC), which was widespread amongst critically-ill 8 patients 1, 2 . 9 Subsequent studies have estimated an incidence of thrombotic events (mainly pulmonary embolism and venous 10 thromboembolism) in the range of 15-30%, but as high as 69%, of intensive care unit (ICU)-admitted patients 3-6 . 11

Moreover, thrombotic complications have been reported in an estimated 6% of patients across general wards, all of 12 whom had received prophylactic anticoagulants 6 . Potential manifestations of this hyper-coagulative state are acute 13 limb ischaemia 7 , deep vein thrombosis 8 , pulmonary embolism and ischaemic stroke [8] [9] [10] [11] . Early estimates of ischaemic 14 stroke prevalence amongst COVID-19 admissions range from 0.9% to 5% amongst severe cases 11, 12 . Interestingly, 15 one small case series identified an apparent increased risk in young adults, many of whom presented with stroke and 16 asymptomatic SARS-CoV-2 infection 12 . This may suggest that thrombotic complications are not restricted to those at 17 risk of more severe disease progression. Definitive evidence, from large prospective studies, for a causal relationship 18 between COVID-19 and stroke is still required 13 . 19

There has been much discussion postulating possible mechanisms underlying the COVID-19 associated coagulopathy 20 and the idea that immunothrombosis, or thromboinflammation, is driving the pro-coagulant state is beginning to 21 gain prominence. Recent studies have identified altered platelet reactivity (and increased platelet-leukocyte 22

interactions) 14 , release of neutrophil extracellular traps (NETs) 15 and endothelial activation 16 in Several studies have identified an increase in plasma VWF associated with COVID-19 16-18 , however, these have 24 concentrated on those with severe disease (ICU versus non-ICU) and have not included concurrent longitudinal 25

analyses of both VWF and other thromboinflammatory markers. As such, the mechanisms underlying the presence 26 of VWF and how this relates to patient morbidity, mortality or recovery remains unclear. 27

The extremely high and persistent D-dimer levels observed in some COVID-19 patients are an indicator of poor 28 prognosis. They indicate ongoing fibrin formation and fibrinolysis but may also suggest that, while still functional, the 29 fibrinolytic system is overwhelmed 19 . Whether this is due to enhanced fibrinolytic resistance or direct inhibition of 30 pro-fibrinolytic factors is unknown. The former may result from a local increase in Factor XIII which, through its fibrin 31 crosslinking activity, stabilises fibrin clots. This is due to both a direct influence of fibrin structure 20 and the 32 incorporation of α2-antiplasmin into the fibrin network 21 . Direct inhibition of fibrinolysis is mediated by the soluble 33 factors plasminogen activator inhibitor-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI), both of which 34

interfere with the normal fibrinolytic activity of tissue plasminogen activator (t-PA). A combination of these 35 processes might be expected to produce persistent fibrin deposits that are resistant to fibrinolysis, as is suggested by 36 COVID-19 lung pathology. 37

The aim of this study is to identify potential haemostatic deficits, and underlying thromboinflammatory mechanisms, 38

in COVID-19 patient plasma using a combination of clinical measurements and functional coagulation assays. The 39 relationship between these parameters and their significance in disease progression and outcome have been 40 addressed by the application of disease severity stratification and longitudinal sampling. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020 . . https://doi.org/10.1101 by their highest disease severity score. All cross-sectional comparisons between the groups were performed using 19 the first available sample, collected as soon as possible after admission. Longitudinal samples for a sub-set of severe 20

patients were collected at 1-2 day intervals. 21

Four healthy control plasma samples were obtained from Manchester University and NHS Trust front line staff at the 23 time of collecting patient plasma. These individuals were asymptomatic and assumed COVID-19 negative but were 24 not tested. A further 16 healthy controls samples, pre-dating the COVID-19 pandemic, were obtained as part of a 25

previous study and were included in these analyses to ensure age/sex matching of controls to COVID-19 patient 26 samples. Of these, 4 were receiving aspirin but none were otherwise anti-coagulated. 27

Whole blood, collected using BD Vacutainers containing 3.2% trisodium citrate, was diluted 2-fold in phosphate 29 buffered saline (PBS) and fractionated by density gradient centrifugation. Platelet rich plasma was removed and 30 centrifuged further to deplete platelets. Platelet poor plasma was stored at -80°C for analysis. Total plasma protein 31 concentration was quantified by BCA assay (Pierce) following manufacturer's protocol. 32

An initial screen of coagulation factors was performed on a small cohort of healthy control (n=4) and COVID-19 34 patient plasma (n=12) using Procartaplex (Thermo-Fisher) mix and match coagulation panels (Factors X, XI, XII, V, VII, 35

VIII, Protein C and Protein S). All were performed following manufacturer's instructions and analysed on a Bio-Plex 36

200 Luminex analyser (Bio-Rad). 37

All subsequent analyses were performed on the full cohort of healthy control (n=20) and COVID-19 patient plasma 38 (n=23) using the following LEGENDplex panels. Human inflammation 13-plex panel (IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-39 1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23 and IL-33) human thrombosis custom 7-plex panel (P-selectin, D-40 dimer, PSGL-1, t-PA, sCD40L, tissue factor and Factor IX) and human fibrinolysis 5-plex panel (fibrinogen,  41 plasminogen, antithrombin, prothrombin and Factor XIII). All were performed using the manufacturer's protocol and 42 suggested dilutions. Analysis was performed using a BD FACSVerse flow cytometer (BD Biosciences) and LEGENDplex 43 data analysis software version 8.0. 44 45 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020 . . https://doi.org/10.1101 Quantification of Thromboinflammatory Markers in Plasma by ELISA 1 Plasma VWF and ADAMTS13 antigen levels were determined by in-house ELISA as described previously 22 , with intra-2 and inter-assay coefficients of variation of 5 and 8% respectively for VWF and 8 and 12% respectively for 3 ADAMTS13 23 . 4

The presence of UL-VWF in plasma was determined by an ELISA-based collagen binding assay 23 . Results are 5 presented as both VWF:CBA (%), in which the signal is normalised to that of healthy controls, and the ratio of 6 VWF:CBA/Ag, in which the extent of collagen binding is normalised by the total VWF antigen determined by ELISA. 7

Commercial ELISA kits were used, following manufacturer's protocols, to quantify α-defensins (human HNP (1-3) 8

ELISA, Hycult Biotech), α2-antiplasmin (human Serpin F2 ELISA, Invitrogen), TAFI (human carboxypeptidase B2/CPB2 9 ELISA, Invitrogen) and PAI-1 (Invitrogen). 10

Sample plasma was warmed to 37°C and diluted 2-fold in Hank's Balanced Salt Solution (HBSS) supplemented with 12 20 mM CaCl2 in clear, flat-bottomed 96-well plates in a final volume of 50 μl. The assay was initiated by the addition 13 of 5 nM (0.5 U/ml) human thrombin (Sigma-Aldrich) at which point the samples were mixed for 10 seconds at 700 14 rpm in the heated chamber of a FluoSTAR Omega microplate reader (BMG Labtech) pre-heated to 37°C. The 15 absorbance at 405 nm was measured at 20 second intervals for a total of 30 minutes. 16

Plasma from 3 healthy controls and 3 patients in each COVID-19 subgroup was diluted as above, in a total volume of 18 200 μl in 12-well chamber slides. These preparations were supplemented with 150 μg/ml AlexaFluor594 labelled 19 fibrinogen (Invitrogen) and 10 μg/ml AlexaFluor647 conjugated α-VWF antibody (Abcam) and pre-warmed to 37°C. 20

Fibrin polymerisation was initiated by the addition of 5 nM (0.5 U/ml) human thrombin and left to occur at 37°C for 1 21

hour. Images were acquired on a Leica SP8 inverted confocal microscope equipped with a heated chamber 22 maintained at 37°C. A 10x/0.40 APO dry objective and zoom factor of 0.75 were used to acquire images of 1550 μm x 23 1550 μm. HyD hybrid detectors were used to detect fibrinogen-594 and VWF-647 with emission gates of 600-642 nm 24

and 691-787 nm, respectively. Images were analysed in ImageJ. 25

Plasma, diluted as above, was pre-warmed to 37°C. The assay was initiated by the addition of 10 nM (1 U/ml) human 27 thrombin and 25 ng/ml rt-PA (Alteplase, Hoffmann La Roche) at which point the samples were placed in the heated 28 chamber of a FluoSTAR Omega plate reader. Absorbance at 405 nm was measured every 30 s for 1 h with continuous 29 double orbital shaking between measurements. 30 31

A total of 23 eligible patients, with sufficient observations to allow stratification of disease severity, were recruited 34 with a median time from patient-reported symptom onset to hospital admission of 8 days. The median age was 58 35 years and 69.6% were male compared with a median age of 67 years and 43.8% male in the healthy control group. 36

The majority of patients (69.6%) tested positive for SARS-CoV-2 by RT-PCR and the remaining 30.4%, with negative 37 RT-PCR, had moderate or severe radiological findings. Frequent co-morbidities amongst patients were diabetes, 38 hypertension (HTN), ischaemic heart disease (IHD), chronic obstructive pulmonary disease (COPD) and asthma (Table  39 1). A total of 82.4% of patients received thromboprophylaxis and 10% received a treatment dose of anti-coagulants. 40

The only complications observed were acute kidney injury (AKI) in 2 moderate patients and pulmonary embolism 41 (PE) in 1 moderate patient ( Table 1) . Death occurred in 1 mild patient (aged 84) and 2 severe patients (aged 74 and 42 81). 43 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.18.20159608 doi: medRxiv preprint

The plasma concentrations of the primary anti-viral cytokines IFN-α and TNF-α were not significantly different 2 between COVID-19 patients and healthy controls (Figure 1) . The peripheral pro-inflammatory response to COVID-19 3 showed significant increases, compared to healthy controls, for all cytokines except IL-1β and IL-12p70 (Figure 1 and 4 Table 1 ). IL-6, IL-8, IL-10, IL-18, IL-23 and IL-33 were universally increased in all COVID-19 sub-groups compared to 5 healthy controls (Figure 1 ) with IL-6 and IL-8 displaying the largest increase (>40-fold and >4-fold, respectively). 6

Other markers of thromboinflammation (P-selectin, PSGL-1 and sCD40L) were all increased ~2-fold when comparing 7 all COVID-19 samples against healthy controls (Table 1) , but only P-selectin was statistically significant (p<0.01). 8

Longitudinal sampling was performed on 4 of the severe COVID-19 patients and has suggested some relationships 9 between inflammatory and thrombotic parameters ( Figure S3 ). The concentrations of IL-6, IL-8 and MCP-1 all 10 decreased over time in patient 21, peaked at day 3 in patient 20 and increased between day 6 and day 10 in patient 11

22. In patients 21 and 22 an inverse IL-18 response was observed. A relationship was observed between the 12 inflammatory response (particularly IL-6) and the α-defensin, VWF and PAI-1 responses. 13

An initial Luminex screen of coagulation factor levels in 4 healthy control samples and 12 COVID-19 patient samples 15 identified no significant difference in the PE fluorescence of beads specific to Factors V, VII, VIII, X, XI and XII, Protein 16

S or Protein C ( Figure S1 ). Factor IX, antithrombin and prothrombin concentrations were within the normal range 17 with no significant differences between the groups ( Table 1) . Compared to heathy controls, there was a significant 18 increase in D-Dimer concentration (determined by Legendplex) in plasma from the severe COVID-19 group 19

(p=0.004), however, all values were still within the normal range ( Table 1) . The limited number of available results 20 from clinical D-dimer tests identified high concentrations (>500 ng/ml) in some patients ( Table 1) . 21 A COVID-19 associated increase in the levels of plasma VWF was identified in this initial multiplex screen and was 22

subsequently quantified by ELISA. Healthy controls were all within the normal range (60-190% of 10 μg/ml) with a 23 mean value of 7.5 ± 1.2 μg/ml. This was significantly increased to 25.9 ± 10.8, 19.4 ± 6.6 and 26.1 ± 7.3 μg/ml in the 24 mild, moderate and severe COVID-19 groups respectively (Figure 2A ). The concentration of ADAMTS13 was also 25 within the normal range (74-142% of 900 ng/ml) for all healthy controls with a mean value of 998 ± 112 ng/ml, but 26 was reduced to 538 ± 163, 582 ± 181 and 589 ± 124 ng/ml in the mild, moderate and severe groups ( Figure 2B ). We 27 also observed a small, but significant, increase (4-6 fold) in neutrophil α-defensins across all COVID-19 sub-groups 28 compared to healthy controls ( Figure 2C ). 29 A significant inverse relationship between VWF and ADAMTS13 concentration was observed as was a clear 30 segregation of the healthy and patient groups ( Figure 2D ). There was also a significant correlation between VWF and 31 IL-6 concentration ( Figure 2E ) and an inverse relationship between ADAMTS13 and IL-6 ( Figure 2F) . A collagen 32 binding assay was used as a measure of VWF multimeric size and activity with the amount of collagen-bound VWF 33

(VWF:CBA) in each sample normalised to the mean of the healthy control samples (100 ± 15.7 %.). In the mild, 34 moderate and severe COVID-19 groups there was significantly higher VWF activity with mean values of 596 ± 422, 35

359 ± 120 and 691 ± 445 %, respectively ( Figure 2G ). The significance of these measurements remained when the 36 activities were normalised by VWF antigen (Ag) levels ( Figure 2H ) and a significant inverse relationship was observed 37 between the ratio of VWF:CBA/Ag and ADAMTS13 concentration ( Figure 2J) . 38

Fibrin formation was monitored in vitro using a turbidity-based assay (Figures 3A and 3B ). An increase in initial rate 40

was observed in all COVID-19 sub-groups with a ~2-fold change in slope being seen in the moderate and severe 41 groups ( Figure 3D ). Confocal imaging of fibrin clots, formed in vitro, was carried out to confirm that the increased 42 initial rate of fibrin formation in patient plasma was the result of structural changes in the fibrin network ( Figure 3C ).

In healthy control plasma (n=3) the fibrin network appeared to be evenly distributed, consisting of fine fibrin fibres 44 with only small and few fibrin clusters ( Figure S2A ). In healthy control 'clots' there was very little VWF staining and it 45 appeared to be largely localised within the small fibrin clusters ( Figure S2B) . A similarly even fibrin distribution was 46 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.18.20159608 doi: medRxiv preprint observed in all mild (n=3) and moderate (n=3) patient 'clots', albeit with larger and more abundant fibrin clusters. 1

Plasma from patient 4 formed fibrin with some much larger fibrin clusters approaching 150 μm in length ( Figure  2 S2A). The most apparent change in fibrin structure was observed in the severe patients 18 and, in particular, patient 3 20 ( Figure S2A) . Again, VWF was co-localised with the large fibrin clusters and, in line with their increased size, was 4 much more abundant (Figure S2B) . 5

The concentration of tissue factor (TF) was within normal range (5.9-200.9 pg/ml) in all healthy controls and all 6 COVID-19 patient samples, except 2 of the moderate cases ( Figure 3E) , with no significant difference in mean values 7 between the groups. The concentration of fibrinogen in healthy controls was generally within either the 8 manufacturer's (0.75-1.7 mg/ml) or the clinical (2-4.5 mg/ml) normal range 24 ( Figure 3E ). Of the 20 healthy controls 9 only 4 were above the upper limit of normal, however, the mean value of 2.51 mg/ml was within range. There was a 10 statistically significant increase in fibrinogen in the moderate and severe COVID-19 sub-groups, values all being 11

above the upper limit of the normal range. A similar pattern of factor XIII (FXIII) concentrations was observed, with 12 14 out of the 20 healthy controls falling below the upper limit of the manufacturer's normal range (6.7-15.3 μg/ml) 13

and a mean value that was within this range (10.9 μg/ml). There was a significant increase in FXIII concentrations in 14

all COVID-19 sub-groups ( Figure 3E ). Analysis of longitudinal samples from patient 21 identified a relationship 15 between FXIII levels and impaired fibrin formation. all severity groups ( Figure 4C ). There appeared to be little effect of infection on the release of t-PA as the 20 concentration in all healthy controls and most moderate and severe COVID-19 patient plasma was within, or 21 marginally above, the normal range of 1.6-8.4 ng/ml ( Figure 4D ). Plasminogen levels were unaffected by infection and were all within the normal range of 79-170 μg/ml ( Table 1) . We observed a significant upregulation of 23 PAI-1 in all COVID-19 sub-groups compared to healthy controls, of which, all but one were within the literature 24 normal range of 20-100 ng/ml 25 , with COVID-19 samples all above this ( Figure 4D ). Analysis of longitudinal samples 25 from patient 21 identified a relationship between PAI-1 concentration and impaired fibrinolysis. The concentrations 26 of α2-antiplasmin were also influenced, with statistically significant increases observed in the mild and moderate 27 COVID-19 sub-groups ( Figure 4E ). In healthy controls the plasma concentrations of α2-antiplasmin and TAFI were 28 largely within the literature normal ranges of 50.4-85.4 μg/ml 16 and 4-15 μg/ml 26 , respectively. The mean α2-29 antiplasmin concentrations in the mild, moderate and severe COVID-19 groups were all above the normal range, as 30 was the mean TAFI concentration in the severe group ( Figure 4E) . 31 32

A similar cytokine signature is present across all COVID-19 severity groups 34

The peripheral cytokine signature observed in this study is similar to that reported previously in a parallel study of 35 the same patients 27 , with low levels of anti-viral cytokines (IFN-α and TNF-α) but substantial increases in pro-36 inflammatory cytokines (IL-6, IL-8, IL-10, IL-18, IL-23 and IL-33). This is true of all sub-groups, in particular the 37 moderate and severe groups, in which the cytokine response is characteristic of ARDS of all causes 28 and is reflected 38 in a progressive increase in total white blood cell and neutrophil counts across the severity groups. Longitudinal 39 analysis of the cytokine signature in severe patients is in agreement with a previous report suggesting the cytokine 40 response diminishes in some patients as the disease progresses in severity and over time which may indicate 41 exhaustion of some immune cell populations producing these cytokines 27 . 42

A screen of factors of the extrinsic, intrinsic and common coagulation cascades and key anti-coagulant pathways was 44 performed in a smaller, initial cohort of samples and ruled out a role of these pathways in COVID-19 associated 45 coagulopathy. Unlike in DIC, which was initially suspected as the cause of thrombotic complications in COVID-19 46 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.18.20159608 doi: medRxiv preprint patients due to high D-dimer and PT 1 , there does not appear to be a consumption of coagulation factors, including 1

Factor IX, which was quantified in the full cohort of samples. This is in agreement with the lack of bleeding 2 phenotype observed in patients with COVID-19-associated coagulopathy 2 . While D-dimer was elevated significantly 3 in the severe COVID-19 group, all values were within the expected normal range for the assay and the available 4 clinical D-dimer measurements, although above the clinical normal range of <500 ng/ml, were far from the 5-20 5 μg/ml range that would suggest a diagnosis of DIC. 6 VWF/ADAMTS13 imbalance is associated with increased IL-6 and neutrophil α-defensins 7

Increased plasma VWF has been suggested, in multiple recent studies 16-18 , to be a key driving force behind COVID-19 8 associated coagulopathy. This is further supported by the existence of VWF-platelet rich thrombi in the lungs of 9

COVID-19 patients post-mortem which have been identified in numerous independent studies 29-31 . Our data is in 10 agreement with this hypothesis as we report a substantial increase in plasma VWF, even in those with mild COVID-19 11 disease. It is likely that this increase in VWF is the result of endothelial activation and Weibel-Palade body exocytosis, 12

which have been shown in vitro to be induced by IL-6 32 . As such, we observed a strong correlation between plasma 13 VWF and IL-6. 14 We also report a substantial decrease in ADAMTS13 antigen in COVID-19 patients which, to date, has only been 15

reported in one small case series 17 . As with VWF, this response is present in all COVID-19 sub-groups and correlates 16

with IL-6. Although VWF and ADAMTS13 have both been implicated in other thrombotic pathologies, they are most 17 often seen as independent risk factors 22, 23 . The fact that there is a strong correlation between VWF and ADAMTS13 18 in this cohort is unusual and may suggest that their increase and decrease, respectively, are driven by the same 19

mediator, most likely IL-6. This is also indicated by longitudinal analysis, in particular that of patient 21, in which 20 normal VWF/ADAMTS13 balance is restored as the IL-6 response diminishes. Other factors implicated in ADAMTS13 21

suppression are age (as with VWF), cytokine inhibition of hepatic synthesis 33 , direct inhibition by IL-6 32 and direct 22

inhibition by neutrophil α-defensins 34 . Interestingly, we report an increase in the plasma concentration of α-23 defensins in COVID-19 patients in our cohort and a robust inverse relationship between this and ADAMTS13 levels 24

(R 2 =0.50, p<0.0001). Neutrophil counts and neutrophil activation (soluble PSGL-1) are both increased in these 25 samples, in line with another recent study 35 , and both correlate with plasma VWF (R 2 =0.29, p<0.01 and R 2 =0.10, 26

p<0.05, respectively). 27

The expected functional consequence of a concurrent increase in VWF and decrease in ADAMTS13 would be an 28 increase in the multimeric size and therefore, activity, of VWF. Indeed, we report a significant increase in VWF 29 collagen binding activity in all COVID-19 sub-groups with some moderate and severe patients exhibiting a >10-fold 30

increase. This would be expected to have an impact on platelet-recruitment and might also enhance platelet 31 aggregation and platelet-leukocyte aggregation which have been observed in recent studies 14, 36 . Platelet counts in 32 healthy controls were similar to that of patients therefore no relationship between increased VWF and platelet 33 depletion could be identified in this cohort of COVID-19 patients. Mild thrombocytopenia has been reported 34 previously in COVID-19 patients 37 but is only evident in three patients in this cohort and there is no apparent 35 relationship between platelet count and VWF. Interestingly, in patient 21, in which VWF levels normalise in later 36 samples, there is a corresponding increase in platelet count into the normal range. 37

Perhaps the most universally altered parameter amongst COVID patient plasma is an increase in initial rate of in vitro 39 fibrin formation. This does not appear to be the result of increased fibrinogen levels, observed here and in previous 40

reports 38, 39 , as there is little variation in initial rate within the healthy control group despite differing fibrinogen 41

concentrations. There is also a relatively weak correlation between fibrinogen concentration and initial rate 42 (R 2 =0.19, p=0.003). Instead, the alteration is likely the result of increased incorporation of VWF into the fibrin 43 network 40, 41 and FXIII-mediated fibrin fibre compaction 42 . This is supported by a significant correlation between 44 initial rate and both VWF (R 2= 0.45, p<0.0001) and FXIII (R 2 =0.30, p=0.0002) and by a longitudinal relationship 45 between FXIII (increasing to above the normal range) and increased initial rate in patient 21. Furthermore, defective 46 fibrin structure, identified by confocal imaging, is more apparent in patients who have FXIII levels above the normal 47 range and particularly high VWF levels. 48 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.18.20159608 doi: medRxiv preprint

In those patients, large fibrin clusters were formed which contained VWF, mirroring the composition of thrombi 1 identified in post-mortem lung examinations in COVID-19 patients 30 . These structures may derive from the fact that 2 FXIII-mediated crosslinking of fibrin results in a higher density of fibres 20 and that FXIII is known to covalently 3 crosslink VWF to fibrin 43 . Although the precise nature of this fibrin structure defect, and its potential impact on clot 4 permeability, are not yet fully understood it is possible that the large fibrin clusters formed may be impermeable 5 which might be expected to influence fibrinolysis (see below). Likely sources of the increased levels of FXIII in COVID-6 19 patients are monocytes, macrophages and platelets recruited to the pulmonary endothelium. Given the relatively 7 normal number of circulating monocytes in all COVID-19 sub-groups, platelets appear to be the likely source of FXIII. 8

Increased numbers of activated platelets have been identified as a common feature amongst COVID-19 patients 14, 36 9

and is indicated in this cohort by increased plasma P-selectin and soluble CD40L. 10 Altered clot structure and endothelium-derived PAI-1 induce fibrinolytic resistance 11

Based on the defective fibrin formation observed in COVID-19 patient plasma herein, and the previous identification 12 of persistent fibrin deposits and hyaline membranes in post-mortem lung samples 30 , we hypothesised that fibrin 13 formed in the pulmonary vasculature and alveolar spaces may be resistant to endogenous fibrinolysis. Using an in 14 vitro assay of t-PA/plasmin-mediated fibrinolysis we have identified a ~2 fold extension of clot lysis times, 15

irrespective of disease severity. This may be influenced, in part, by the altered fibrin structure described above and 16 this is supported by a correlation between the initial rate of fibrin formation and time to clot lysis (R 2 =0.75, 17

p<0.0001). 18

There are four main inhibitory factors that supress fibrinolysis by the t-PA/plasmin pathway, 19 α2-macroglobulin and TAFI. Although they are all primarily produced by the liver, their plasma concentrations can be 20 potentially influenced by inflammatory and immune responses known to be involved in COVID-19. The factor most 21 significantly affected by COVID-19 seems to be PAI-1, with almost all patients exhibiting increased levels despite 22

relatively normal levels of t-PA. The importance of this imbalance is reflected in the correlation between PAI-1 and 23

an increased time to clot lysis (R 2 =0.22, p<0.002). This is unsurprising as PAI-1 is known to be released from the 24 activated endothelium, reported in a previous COVID-19 cohort 16 and evident in this cohort by increased plasma 25 VWF, FVIII and P-selectin. Given the size of the vascular bed in the lungs this is likely to account for the majority of 26 the PAI-1 increase, although there may also be a contribution from monocytes and macrophages in the pulmonary 27 vasculature. Increased PAI-1 has been linked to obesity and identified in non-diabetic obese patients (BMI >30) 44 , 28 however, most participants in this study had a BMI <30 and this is unlikely to account for the large observed 29

increase. 30

The impact of COVID-19 on the levels of α2-antiplasmin and TAFI, released locally at low levels by activated platelets, 31

is arguably less significant. In the case of α2-antiplasmin there is a reasonably strong correlation between α2-32 antiplasmin and time to clot lysis (R 2 =0.27, p=0.0003) indicating a disproportionate inhibitory effect. This is likely to 33 be due to an enhancement of α2-antiplasmin's inhibitory potential caused by the concurrent increase in FXIII, thus 34 increasing its incorporation into the fibrin network as it forms. 35

It should be noted that the haemostatic alterations identified in this cohort, and thrombotic complications of 37 COVID19 reported previously 5 , have occurred despite most patients receiving thromboprophylaxis and, in some 38 cases, treatment doses of anti-coagulants. Therefore, this may have implications in the ongoing management of such 39 complications in patients who may require higher prophylactic doses while hospitalised and extended 40 anticoagulation post-discharge. Until we have a complete understanding of the mechanism involved it may be 41 difficult to predict which common anti-coagulant therapy, if any, is most appropriate. Given the apparent role of FXIII 42

and VWF in the defective coagulation, experimental therapies targeting these factors such as the FXIII inhibitor 43 tridegin 45 and rADAMTS13 46, 47 , are potentially worth pursuing. The apparent fibrinolytic resistance in patients may also impact on the efficacy of rt-PA thrombolysis to treat hyperacute ischaemic stroke or massive 45 pulmonary embolism complicating SARS-CoV-2 infection and, again, experimental avenues might need to be 46 explored to overcome this. Potential new thrombolytic therapies such as rADAMTS13, which is unlikely to be 47 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020 . . https://doi.org/10.1101 influenced by fibrinolytic inhibition, or α2-antiplasmin inhibitors, with the ability to correct the defective fibrinolysis 1 thereby restoring the efficacy of rt-PA thrombolysis 48 , are both viable options that should be explored. 2

This work was funded by Medical Research Foundation Fellowship (MRF-076-0004-RG-SOUT-C0756) awarded to K. 4 South. This report is independent research supported by the North West Lung Centre Charity and the National 5

Institute for Health Research Manchester Clinical Research Facility at Manchester University NHS Foundation Trust 6 (Wythenshawe). We acknowledge the Manchester Allergy, Respiratory and Thoracic Surgery Biobank for supporting 7 this project and thank the study participants for their contribution. Angela Simpson, Alexander Horsely and Tim 8

Felton are supported by the Manchester Biomedical Research Centre. Imaging was performed in the University of 9

Manchester Bioimaging core facility. Flow cytometry and LEGENDplex assays were performed in the University of 10

Manchester Flow Cytometry core facility. 11 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . 

Diabetes Type 2 1/16 (6.3%) Type 2 4/18 (22.2%) Type 2 1/6 (16.7%) Type 2 1/6 (16.7%) Type 2 2/6 (33.3%) COPD 0/16 (0%) 4/19 (21.1%) 2/6 (33.3%) 1/7 (14.3%) 1/6 (16.7%) Asthma 0/16 (0%) 1/18 (5.6%) 0/6 (0%) 0/6 (0%) 1/6 (16.7%) IHD CAD 1/16 (6.3%) Angina 2/18 (11.1%) 0/6 (0%) Angina 1/6 (16.7%) Angina 1/6 (16.7%) HTN 4/16 (25%) 6/18 (33.3%) 1/6 (16.7%) 4/6 (66.7%) 1/6 (16.7%)

N/A 8 (4. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020 . . https://doi.org/10.1101 from PE fluorescence intensity. Results are presented as mean ± S.D. for both healthy control (n=20) and COVID-19 10 patient plasma (n=23). Comparison of the COVID-19 population and healthy controls was performed using a Whitney test. Comparison of COVID-19 sub-groups with healthy controls was performed using a Kruskal-Wallis test 12

with Dunn's correction for multiple comparisons (*<0.05, **p<0.01, ***p<0.001 and ****p<0.0001). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020 . . https://doi.org/10.1101 ELISA. The plasma concentrations of α-defensins were determined using a commercial ELISA kit (C). Each data point 6

represents the mean of duplicate concentration values determined for each sample. Results are presented as mean 7 ± S.D. for both healthy control (n=20) and COVID-19 patient plasma (n=23). Linear regression (solid line) with 95% 8 confidence intervals (dotted lines) are included to show the relationship between VWF and ADAMTS13 (D) and 9

between plasma IL-6 and VWF (E) or ADAMTS13 (F). In each case Spearman's rank coefficient correlation tests were 10 performed to determine R 2 values. The effect of VWF/ADAMTS13 imbalance on the prevalence of high molecular 11 weight (HMW) VWF multimers in plasma was determined by collagen binding assay. The amount of HMW VWF 12 (relative to that in the healthy control group) (G) was normalised by total VWF antigen to give the ratio of CBA/Ag 13 (H is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020 . . https://doi.org/10.1101 for each sample over the first 3 minutes (9 measurements) were fitted to a linear regression model to determine the 7 initial rate of change of fibrin formation (slope). (C), the structure of the fibrin network, formed in the presence of 8

AlexaFluor594 labelled fibrinogen (red), was visualised by confocal microscopy. Shown are example images from one 9 sample in each subgroup. Scale bars represent 200 μm. Further imaging of a selection of samples from each group 10 was also performed and can be found in Supplementary Figure 2. (D) , the initial rate values for fibrin formation in 11 each sample were determined from 4 independent experiments and are presented as mean ± S.D. (E), Plasma 12

concentrations of tissue factor (TF), fibrinogen (Fgn) and Factor XIII (FXIII) were determined by LEGENDplex™ assay 13 (human fibrinolysis 5-plex and human thrombosis custom 7-plex panels) as per manufacturer's protocol. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.18.20159608 doi: medRxiv preprint Turbidity assays, in which fibrin formation is initiated by the addition of thrombin in the presence of t-PA, were 7 performed using healthy control (n=20) and COVID-19 patient plasma (n=23). Shown are example traces from 3 8 healthy controls and a mild COVID-19 patient (A) and 3 severe COVID-19 patients (B). For each, absorbance 9

measurements are mean ± S.D. from 4 independent experiments. From each trace the mean time to clot lysis was 10 manually determined (white arrows) and are presented for each sample as mean ± S.D. from the 4 replicates (C is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.18.20159608 doi: medRxiv preprint Type II pneumocytes of the lung epithelium through binding to its 'receptor' angiotensin-converting enzyme (ACE)-2. 5

(2), infection elicits a type-1 interferon response (IFN-α) triggering the release of type-2 interferons (IFN-γ) and pro-6 inflammatory cytokines, including tumor necrosis factor (TNF)-α, from the epithelial cells and tissue resident 7 leukocytes.

(3), resident macrophages, monocyte-derived macrophages and infiltrating monocytes express 8 coagulation factor XIII (FXIII) and plasmin activator inhibitor (PAI)-1. (4), endothelial activation induces Weibel-Palade 9 body exocytosis and the release of von Willebrand factor (VWF). Concurrent depletion of ADAMTS13 results in the 10 formation of ultra large (UL)-VWF multimers with high platelet reactivity and the formation of platelet aggregates. 11

(5), the activated endothelium further contributes to increased plasma PAI-1 and recruited platelets release FXIII. 12

Together, these changes drive the formation of fibrinolytic resistant fibrin deposits. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.18.20159608 doi: medRxiv preprint patients. The plasma concentrations of coagulation factors were determined by ProcartaPlex™ assay (coagulation 6 panels 1-3) as per manufacturer's protocol. Each data point represents the mean of duplicate PE fluorescence 7 measurements. Results are presented as mean ± S.D. for both healthy control (n=4) and COVID-19 patient plasma 8 (n=11-12). In the moderate group a sampling error reduced the number of FXI readings to n=3. Comparison of the 9 COVID-19 population and healthy controls was performed using a Mann-Whitney test and showed no significant 10 difference. 11 12 13 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.18.20159608 doi: medRxiv preprint 1 Figure S2 . The microscopic structure of fibrin in in vitro 'clots'. A, fibrin clots, formed in plasma from 3 2 healthy controls and 3 patients from each COVID-19 sub-group, were imaged by confocal microscopy. 3

Selection of samples from COVID-19 groups was based on FXIII concentrations (numbers in brackets) which 4 were either within, or above, the normal range of 6.7-15.3 μg/ml. B, example images at higher magnification 5

showing co-localisation (yellow) of fibrin clusters and VWF staining. Scale bars represent 200 μm. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.18.20159608 doi: medRxiv preprint all other healthy and patient samples. The x-axis refers to the number of days elapsed since ICU admission. Data for 6 each individual parameter has been normalised for each sample relative to the maximal response observed in that 7 patient series. Due to the low volume of plasma available for some time points in patients 20 and 23, fibrin 8 formation and fibrinolysis assays were not performed. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.18.20159608 doi: medRxiv preprint

Abnormal coagulation parameters are associated with poor prognosis in 2 patients with novel coronavirus pneumonia

Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings 5 and other Parameters of Hemostasis

Incidence of thrombotic complications in critically ill ICU patients with COVID-8 19

Prevalence of venous thromboembolism in patients with severe novel 10 coronavirus pneumonia

High incidence of 12 venous thromboembolic events in anticoagulated severe COVID-19 patients

Venous and arterial thromboembolic complications in COVID-19 patients 15 admitted to an academic hospital in

Acute limb ischemia in patients with COVID-19 pneumonia

Upsurge of deep venous thrombosis in patients affected by COVID-19: 19 Preliminary data and possible explanations

Characteristics of ischaemic stroke associated with 22 COVID-19

COVID-19 24 presenting as stroke

SARS2-CoV-27 2 and Stroke in a New York Healthcare System

Large-Vessel Stroke as a Presenting Feature 30 of Covid-19 in the Young

EXPRESS: Preceding Infection and Risk of 32 Stroke: An Old Concept Revived by the COVID-19 Pandemic

Neutrophil Extracellular Traps (NETs) Contribute to 39 Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional 43 study

ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in 45 COVID-19 inpatients

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter 49 prospective cohort study

Fibrinolysis and COVID-19: a plasmin paradox

The effect of blood 53 coagulation factor XIII on fibrin clot structure and fibrinolysis

The antifibrinolytic function of factor XIII is exclusively expressed through 1 alpha(2)-antiplasmin cross-linking

High VWF, low 3 ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women

The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary 9 hypertension

How I use fibrinogen replacement therapy in acquired bleeding

PAI-1 produced ex vivo by 13 human adipose tissue is relevant to PAI-1 blood level

Plasma TAFI levels influence the clot lysis time in 15 healthy individuals in the presence of an intact intrinsic pathway of coagulation

Longitudinal immune 18 profiling reveals distinct features of COVID-19 pathogenesis

Cytokine profile in plasma of severe 21 COVID-19 does not differ from ARDS and sepsis

Pulmonary post-mortem findings in a series of COVID-19 24 cases from northern Italy: a two-centre descriptive study

Pulmonary and Cardiac Pathology in 26 Covid-19: The First Autopsy Series from New Orleans

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ 29 thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine

Effects of inflammatory cytokines on the release and 31 cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow

Inflammatory cytokines inhibit ADAMTS13 synthesis in 34 hepatic stellate cells and endothelial cells

Human 36 neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP

Immunothrombotic Dysregulation in COVID-19 Pneumonia is Associated with 41 Respiratory Failure and Coagulopathy. Circulation. 0

Platelet activation and platelet-monocyte aggregates formation trigger tissue factor 44 expression in severe COVID-19 patients

COVID-19-46 associated immune thrombocytopenia

Hypofibrinolytic state and high thrombin generation may play a major role in sars-cov2 associated 49 thrombosis

Prediction of severe illness due to 51 COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count

Kelchtermans 53 H and de Laat B. Thrombin-dependent Incorporation of von Willebrand Factor into a Fibrin Network

Modulating the rate of fibrin formation and clot structure attenuates 2 microvascular thrombosis in systemic inflammation

Factor XIII stiffens fibrin clots by causing fiber 4 compaction

Covalent crosslinking of von Willebrand factor to 6 fibrin

Plasminogen Activator Inhibitor-1 Level 8 Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects

Inhibitors of blood coagulation factor XIIIa

ADAMTS13-mediated thrombolysis 12 of t-PA-resistant occlusions in ischemic stroke in mice

Enhanced activity of an ADAMTS-13 variant 14 (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic 15 stroke

Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique 17 Effects of Plasminogen Activation and alpha2-Antiplasmin Inactivation